

# NCI-THYROID CANCER CLINICAL TRIALS

## PLANNING MEETING

NOVEMBER 10-11, 2013 • FAES ACADEMIC CENTER

NIH CAMPUS, BUILDING 10

BETHESDA, MD

### *Agenda*

#### **SUNDAY: NOVEMBER 10, 2013**

***General Session will take place in FAES Academic Center Rooms 1-4***

***Introduction*** – 1:00-1:15pm

Welcome and Logistics

***Matt Ringel, MD Ohio State University***

***Gary Clayman, DMD MD UT MD Anderson Cancer Center***

#### **I. 1:15-4:00 pm- Overview of Papillary Thyroid Carcinoma- State of Knowledge**

a. 1:15-1:45 pm

Statistics (frequency, stage, treatments utilized nationally)

***Steven I. Sherman, MD UT MD Anderson Cancer Center***

b. 1:45-2:00 pm

Early Stage Surgery + Managing the Central Compartment Lymphatics

***Martha Zeiger, MD Johns Hopkins University***

c. 2:00-2:15 pm

Surgery in the Management of Recurrent/Persistent Differentiated Thyroid Cancer

***Gregory Randolph, MD Harvard University***

d. 2:15-2:45 pm

Ultrasound and Nuclear Imaging

***Susan Mandel, MD University of Pennsylvania***

e. 2:45-3:05 pm

Surveillance and Monitoring

***Bryan Haugen, MD University of Colorado***

f. 3:05-3:20 pm

Clinical Trials of Active Surveillance

***Akira Miyauchi, MD, Kuma Hospital Japan***

g. 3:20-3:35 pm

VA Study of Initial Management of Thyroid Cancer

***Jeff Moley, MD, Washington University***

h. 3:35-4:00 pm

Discussion

**Break- 4:00-4:20pm**

*Snacks available for purchase in the ACRF Café located on the 2<sup>nd</sup> floor*

II. 4:20-6:00 pm

**Status of Biomarkers in Thyroid Cancer Diagnosis and As a Predictor of Natural History or Response to Therapy**

a. 4:20-4:55 pm

TCGA overview and results

**Tom Giordano, MD University of Michigan**

b. 4:55-5:05 pm

Discussion and Questions

c. 5:05-5:40 pm

Diagnostic, Predictive Molecular Thyroid Pathology and Biomarkers

**Yuri Nikiforov, MD, Ph.D. University of Pittsburgh**

d. 5:40-5:50 pm

Discussion and Questions

**Break- 5:50-6:30pm**

*Dinner Buffet for Non Federal Attendees Sponsored by the Devlin Fund of the Fox Chase Cancer Center will be set up in upper foyer of FAES Academic Center. Federal Government employees should go the ACRF Café to purchase dinner*

III. 6:30-7:00 pm

Overview of Steering Committee/Cooperative Group Structure

**John Ridge, MD, PhD., Fox Chase Cancer Center**

IV. 7:00-8:00 pm

Overview of the Four Focus Areas and Goals for Break Out Groups

**Gary Clayman, DMD, MD UT MD Anderson Cancer Center**

V. 8:00-9:30 pm

**Break Out Groups (First Phase Development of Prioritized Focused Questions)**

Group I.

Primary PTCs: Active Surveillance vs. Surgery **Rooms 1-4**

**Group Leaders: Mike Tuttle, MD Memorial Sloan Kettering, and Electron Kebebew, MD NCI**

Group II.

Primary PTC: Extent of Initial Surgery **Room 6**

**Group Leaders: Gary Clayman, DMD, MD UT MD Anderson Cancer Center, and Steve Sherman, MD UT MD Anderson Cancer Center**

Group III.

Residual or Recurrent PTC: Active Surveillance vs. Surgery or Other Local Therapy **Room 5**

**Group Leaders Matt Ringel, MD Ohio State University, and Ralph Tufano, MD Johns Hopkins University**

Group IV.

Quality of Life Measures After Surgery or I-131 Therapy **Room 7**

**Group Leaders: Herb Chen, MD, University of Wisconsin, and Bryan Haugen, MD University of Colorado**

## **MONDAY: NOVEMBER 11, 2013**

- I. 7:00-9:00 am **Break out Groups (*Defining Critical Elements and Design*)**
- Group I. Primary PTCs: Active Surveillance vs. Surgery **Rooms 1-4**  
**Group Leaders: Mike Tuttle, MD Memorial Sloan Kettering, and Electron Kebebew, MD NCI**
- Group II. Primary PTC: Extent of Initial Surgery **Room 6**  
**Group Leaders: Gary Clayman, DMD, MD UT MD Anderson Cancer Center, and Steve Sherman, MD UT MD Anderson Cancer Center**
- Group III. Residual or Recurrent PTC: Active Surveillance vs. Surgery or Other Local Therapy **Room 5**  
**Group Leaders: Matt Ringel, MD Ohio State University, and Ralph Tufano, MD Johns Hopkins University**
- Group IV. Quality of Life Measures After Surgery or I-131 Therapy **Room 7**  
**Group Leaders: Herb Chen, MD, University of Wisconsin, and Bryan Haugen, MD University of Colorado**

**Break- 9:00-9:30 am** Snacks available for purchase in the ACRF Café located on the 2<sup>nd</sup> floor

### **General Session to resume in Rooms 1-4**

- II. 9:30-10:00 am Group I Summary Presentation  
**Mike Tuttle, MD Memorial Sloan Kettering**
- III. 10:00-10:30 am Group II Summary Presentation  
**Gary Clayman, DMD, MD UT MD Anderson Cancer Center**
- IV. 10:30-11:00 am Group III Summary Presentation  
**Matt Ringel, MD Ohio State University**
- V. 11:00-11:30 am Group IV Summary Presentation  
**Bryan Haugen, MD University of Colorado**
- VI. 11:30-12:00 pm Meeting Summarization and Next Steps  
**Gary Clayman, DMD, MD UT MD Anderson Cancer Center Group I and II and Matt Ringel MD Ohio State University Group III and IV**
- VII. 12:00 pm Adjournment

*Lunch available for purchase in the ACRF Café located on the 2<sup>nd</sup> floor*

VIII. 1:00-2:30 pm

Cooperative Group Leadership Meeting **Room 7**

***Gary Clayman, DMD, MD, UT MD Anderson Cancer Center***

***Matt Ringel, MD, Ohio State University***

***David Brizel, Duke University***

***David Adelstein, MD, Cleveland Clinic***

***John Ridge, MD, Ph.D., Fox Chase Cancer Center***

***Robert Ferris MD, Ph.D., University of Pittsburgh***

***Quynh Le, MD, Stanford University***

***Jack Lee, PhD, UT MD Anderson Cancer Center***

***Rita Axelrod, MD, Jefferson Medical Oncology***

***Jeff Moley, MD VA Group***

***David Eisele, MD, John Hopkins University***

***Bhupinder Mann, MBBS, NCI Cancer Therapy Evaluation Program (CTEP)***

***Domenic Reda PhD, VA Group***